Targeting TLR4 during vaccination boosts MAdCAM-1+ lymphoid stromal cell activation and promotes the aged germinal center response
File(s)abk0018 technical edit_aD_symplectic.pdf (11.25 MB)
Accepted version
OA Location
Author(s)
Type
Journal Article
Abstract
The failure to generate enduring humoral immunity after vaccination is a hallmark of advancing age. This can be attributed to a reduction in the germinal center (GC) response, which generates long-lived antibody-secreting cells that protect against (re)infection. Despite intensive investigation, the primary cellular defect underlying impaired GCs in aging has not been identified. Here, we used heterochronic parabiosis to demonstrate that GC formation was dictated by the age of the lymph node (LN) microenvironment rather than the age of the immune cells. Lymphoid stromal cells are a key determinant of the LN microenvironment and are also an essential component underpinning GC structure and function. Using mouse models, we demonstrated that mucosal adressin cell adhesion molecule-1 (MAdCAM-1)-expressing lymphoid stromal cells were among the first cells to respond to NP-KLH + Alum immunization, proliferating and up-regulating cell surface proteins such as podoplanin and cell adhesion molecules. This response was essentially abrogated in aged mice. By targeting TLR4 using adjuvants, we improved the MAdCAM-1+ stromal cell response to immunization. This correlated with improved GC responses in both younger adult and aged mice, suggesting a link between stromal cell responses to immunization and GC initiation. Using bone marrow chimeras, we also found that MAdCAM-1+ stromal cells could respond directly to TLR4 ligands. Thus, the age-associated defect in GC and stromal cell responses to immunization can be targeted to improve vaccines in older people.
Date Issued
2022-05-06
Date Acceptance
2022-03-15
Citation
Science Immunology, 2022, 7 (71), pp.1-17
ISSN
2470-9468
Publisher
American Association for the Advancement of Science
Start Page
1
End Page
17
Journal / Book Title
Science Immunology
Volume
7
Issue
71
Copyright Statement
© 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. This is the author’s version of the work. It is posted here by permission of the AAAS for personal use, not for redistribution. The definitive version was published in Science Immunology on 17, 6 May 2022 DOI: https://www.science.org/doi/10.1126/sciimmunol.abk0018
Sponsor
BBSRC
Medical Research Council (MRC)
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/35522725
Grant Number
BB/N011740/1
MR/V009591/1
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2022-05-06